Deepak Gupta, Associate Director and Senior Consultant at Medanta Hospital, shared on LinkedIn:
“Complete Response in Advanced HCC: SBRT + Immunotherapy – A Winning Combination
Patient: 12 cm advanced HCC, AFP 2,100,000 ng/mL
The approach:
- SBRT to target the bulky lesion + trigger immunogenic response
- Atezolizumab + Bevacizumab as first-line maintenance
The result:
- Complete radiological response
- AFP normalized (2.1 Lakh → 5 ng/mL)
- Excellent quality of life maintained
The takeaway:
- Local destruction (SBRT) + systemic checkpoint inhibition (Atezo/Bev) — combined modality therapy is redefining outcomes in advanced HCC.
This is the new standard of care.”
Read also “PRODIGE 81-TRIPLET-HCC: Ipilimumab Added to Atezolizumab and Bevacizumab in Advanced HCC” on OncoDaily.
